Head to Head Review: Moderna (NASDAQ:MRNA) and BioStem Technologies (OTCMKTS:BSEM)

BioStem Technologies (OTCMKTS:BSEM) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and target prices for BioStem Technologies and Moderna, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioStem Technologies	0	1	0	1	3.00
Moderna	4	13	7	0	2.12

BioStem Technologies presently has a consensus price target of $9.00, indicating a potential upside of 117.39%. Moderna has a consensus price target of $76.72, indicating a potential downside of 61.42%. Given BioStem Technologies’ stronger consensus rating and higher possible upside, research analysts clearly believe BioStem Technologies is more favorable than Moderna.

Volatility & Risk

BioStem Technologies has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioStem Technologies and Moderna”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioStem Technologies	$292.21 million	0.25	-$28.56 million	($1.60)	-2.59
Moderna	$1.94 billion	40.84	-$2.82 billion	($7.99)	-24.89

BioStem Technologies has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioStem Technologies and Moderna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioStem Technologies	N/A	N/A	N/A
Moderna	-141.43%	-28.30%	-19.39%

Insider and Institutional Ownership

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BioStem Technologies beats Moderna on 9 of the 15 factors compared between the two stocks.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.